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Introduction: ‘Patient-specific’ induced pluripotent stem cells (iPSCs) are attractive because they can generate
abundant cells without the risk of immune rejection for cell therapy. Studies have shown that iPSC-derived
mesenchymal stem cells (iMSCs) possess powerful proliferation, differentiation, and therapeutic effects. Recently,
most studies indicate that stem cells exert their therapeutic effect mainly through a paracrine mechanism other
than transdifferentiation, and exosomes have emerged as an important paracrine factor for stem cells to reprogram
injured cells. The objective of this study was to evaluate whether exosomes derived from iMSCs (iMSCs-Exo) possess
the ability to attenuate limb ischemia and promote angiogenesis after transplantation into limbs of mice with femoral
artery excision.
Methods: Human iPSCs (iPS-S-01, C1P33, and PCKDSF001C1) were used to differentiate into iMSCs in a modified
one-step method. iMSCs were characterized by flow cytometry and multipotent differentiation potential analysis.
Ultrafiltration combined with a purification method was used to isolate iMSCs-Exo, and transmission electron
microscopy and Western blotting were used to identify iMSCs-Exo. After establishment of mouse hind-limb ischemia
with excision of femoral artery and iMSCs-Exo injection, blood perfusion was monitored at days 0, 7, 14, and 21;
microvessel density in ischemic muscle was also analyzed. In vitro migration, proliferation, and tube formation
experiments were used to analyze the ability of pro-angiogenesis in iMSCs-Exo, and quantitative reverse-transcriptase
polymerase chain reaction and enzyme-linked immunosorbent assay were used to identify expression levels of
angiogenesis-related molecules in human umbilical vein endothelial cells (HUVECs) after being cultured with iMSCs-Exo.
Results: iPSCs were efficiently induced into iMSC- with MSC-positive and -negative surface antigens and osteogenesis,
adipogenesis, and chondrogenesis differentiation potential. iMSCs-Exo with a diameter of 57 ± 11 nm and expressed
CD63, CD81, and CD9. Intramuscular injection of iMSCs-Exo markedly enhanced microvessel density and blood
perfusion in mouse ischemic limbs, consistent with an attenuation of ischemic injury. In addition, iMSCs-Exo could
activate angiogenesis-related molecule expression and promote HUVEC migration, proliferation, and tube formation.
Conclusion: Implanted iMSCs-Exo was able to protect limbs from ischemic injury via the promotion of angiogenesis,
which indicated that iMSCs-Exo may be a novel therapeutic approach in the treatment of ischemic diseases.* Correspondence: wangy63cn@126.com; dengzf63@126.com
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Stem cells are undifferentiated cells that are present in
the embryonic, fetal, and adult stages of life and are de-
fined by their ability to self-renew and differentiate into
multiple lineages [1,2]. Stem cells have unique character-
istics of high proliferation, specific migration, and the
potential to differentiate into many different reparative
or replacement cell types. Within the last few years, the
important role of stem cells in the field of cell therapy
has begun to be recognized, and remarkable progress in
both basic research and clinical studies has confirmed
that stem cells exert positive therapeutic effects in alleviat-
ing tissue injury after ischemia, including myocardial in-
farction [3,4], brain ischemia [5,6], and limb ischemia [7,8].
It has been well established that bone marrow-derived
mesenchymal stem cells (BMSCs) are an ideal cell
source for autologous cell-based therapy because of their
highly proliferative and self-regenerative capability,
powerful plasticity, and low immunogenicity [9,10].
However, several disadvantages restrict BMSC clinical
applications in autologous transplantation: because they
are adult somatic cells, the proliferation and differenti-
ation capability of BMSCs decrease after a number of
passages in culture. In addition, their proliferation and
differentiation potential decline significantly with in-
creasing age- and aging-related disorders. In addition,
only a limited number of BMSCs can be obtained ini-
tially from a single donor, limiting their further applica-
tion [11,12]. Recent advances in stem cell technology
have enabled the generation of patient-specific induced
pluripotent stem cells (iPSCs) from adult somatic cells,
and these iPSCs are able to differentiate into expandable
progenitor cells and mature cells [13]. iPSCs exhibit
similar properties with embryonic stem cells (ESCs) in
self-renewal and differentiation capacity; one distinct
advantage over ESCs is that they are patient-specific
and thus theoretically can overcome the need for im-
munosuppression in the recipient. It has been reported
that iPSCs can generate unlimited amounts of early-
passage patient-specific MSCs with consistent quality.
Induced pluripotent stem cell-derived mesenchymal
stem cells (iMSCs) are a promising cell source for au-
tologous cell therapies in regenerative medicine be-
cause of their more powerful therapeutic function
compared with BMSCs [14,15].
Although it has been demonstrated that MSCs exhibit
advantages in cell therapy, one potential challenge is the
acquisition of genetic and epigenetic alterations. After
long-term culture, MSCs become immortalized and spon-
taneously transform on account of enhanced chromosome
instability that is associated with the dysregulation of telo-
mere activity and cell cycle-related genes, which can result
in tumorigenesis when injected in multiple organs [16]. In
addition, Jeong et al. found that the transplantation ofshort-term MSCs cultured into mice can form malignant
tumors [17]. Thus, how to fully use the advantages of
MSCs while avoiding disadvantages such as tumor forma-
tion is an important step toward applying them to clinical
therapy for diseases.
Recently, accumulating evidence has indicated that
stem cells exert their therapeutic action mainly via se-
creting molecules, such as growth factors, cytokines,
chemokines, and extracellular microvesicles, into their
surroundings via a paracrine mechanism [18]. Among
these paracrine molecules, exosomes show unique func-
tions in disease diagnosis and therapy [19]. Exosomes
are endosomal-origin small-membrane vesicles with a
diameter of 40 to 100 nm and are formed in multivesi-
cular bodies (MVBs) by invagination of the endosomal
membrane and then released into the extracellular space
when MVBs fuse with the plasma membrane [20]. Re-
cent studies have indicated that exosomes derived from
BMSCs can promote angiogenesis in ischemic tissue and
attenuate tissue injury after an ischemic injury [21-23].
In addition, it has been confirmed that exosomes derived
from MSCs are immune-tolerant, an important property
for clinical applications [24]. Thus, we hypothesized that
exosomes derived from iMSCs (iMSCs-Exo) may also
exhibit similar functions in reducing tissue injury after
ischemia.
In the present study, we investigated the therapeutic
effects of iMSCs-Exo in a mouse hind-limb ischemic
model. Consistent with our hypothesis, we found that
iMSCs-Exo could significantly attenuate limb ischemia.
We further observed a remarkable microvessel density
increase and blood perfusion recovery in the mice ische-
mic limb, which indicated that pro-angiogenesis may be
one reason for iMSCs-Exo to alleviate ischemic diseases.
An in vitro study demonstrated that iMSCs-Exo can pro-
mote human umbilical vein endothelial cell (HUVEC) mi-
gration, proliferation, and tube formation. Furthermore,
iMSCs-Exo can promote angiogenesis-related gene ex-
pression and protein secretion in HUVECs. To the best of
our knowledge, this is the first study to suggest that
iMSCs-Exo also exhibit a pro-angiogenesis function,
which indicates that iMSCs-Exo can become a novel regu-
lator in iMSC-based ischemic injury therapy.
Methods
The use of human iPSCs in this study was approved
by the local ethics committee of Nanchang University
(2 October 2011).
Generation of mesenchymal stem cells from human
induced pluripotent stem cells
Three human iPSC lines were used in the generation of
MSCs. The first human iPSC line (iPS-S-01) was pro-
vided by the Institute of Biochemistry and Cell Biology
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Liao and Xiao [25]. Two additional iPSC lines—iPSCs
(C1P33) and iPSCs (PCKDSF001C1)—were provided by
the South China Institute for Stem Cell Biology and
Regenerative Medicine Group of the Chinese Academy
of Sciences in agreement with Duan-qing Pei [26]. The
iPSCs were routinely cultured and expanded on human
ESC-Qualified BD Matrigel (BD Biosciences, Sparks,
MD, USA) in six-well plates in mTESR1 (StemCell
Technologies, Vancouver, BC, Canada) [27]. When iPSCs
were 90% confluent, mTESR1 was replaced with MSC
medium, which contained Dulbecco’s modified Eagle’s
medium (DMEM)-low glucose (Corning, Tewksbury,
MA, USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco, Grand Island, NY, USA) and 2 mM
L-Glutamine [28]. The MSC medium was changed
every 2 days. After 14 days in culture, the cells were
trypsinized (0.25% trypsin/1 mM EDTA; Gibco) and serially
reseeded thereafter in 0.1% gelatin-coated 25- and 75-cm2
cell culture flasks (Corning) at a density of 1 × 105/mL in
MSC medium. When cells were confluent in 75-cm2 cell
culture flasks, they were considered passage 1. Usually, at
passage 4, the cells demonstrated a morphology similar to
that of fibroblast-like cells and were used to analyze iMSC
phenotypic characteristics, differentiation potential, and
further experiments.
Flow cytometry analysis
iPSC and iMSC surface antigens were analyzed by using
flow cytometry. In total, 5 × 105 cells were incubated
with 1% bovine serum albumin (BSA) (Gibco) for 30 mi-
nutes to block non-specific antigens. The following con-
jugated monoclonal antibodies (BD Biosciences) were
used at the concentration recommended by the manu-
facturer: CD29-PE, CD34-APC, CD44-FITC, CD45-
FITC, CD73-PE, CD90-PE. CD105-FITC, CD133-PE,
CD146-PE, and HLA-DR-PE. Non-specific fluorescence
was determined by incubation of similar cell aliquots
with isotype-matched mouse monoclonal antibodies
(BD Biosciences). After two washes in 1% BSA, the cells
were resuspended in 200 μL of 1% BSA and analyzed by
using the guava easyCyte™ system (Millipore, Billerica,
MA, USA).
Multipotent differentiation potential of induced
pluripotent stem cell-derived mesenchymal stem cells
Osteogenesis, adipogenesis, and chondrogenesis were
examined to determine the iMSC multipotent differenti-
ation potential. For osteogenic induction, 5 × 104 iMSCs
were seeded in 24-well plates until 90% confluence and
replaced with osteogenesis medium (Gibco). The cells
cultured in MSC medium served as control. After
21 days, the cells were fixed with 4% paraformaldehyde
and stained with Alizarin Red to detect areas ofmineralized calcium. For adipogenic induction, 5 × 104
iMSCs were seeded in 24-well plates until complete con-
fluence, and differentiation was induced by adipogenesis
medium (Gibco). The cells cultured in MSC medium
served as the control. After 21 days, the cells were fixed
with 4% paraformaldehyde and stained with Oil Red O.
For chondrogenic induction, 1 × 106 cells were centri-
fuged in a 15-mL polypropylene falcon tube to obtain a
pellet, and chondrogenic medium (Gibco) was gently
added to the pellet. After 21 days, the pellet was fixed
with 4% paraformaldehyde and embedded in optimum
cutting temperature compound (OCT) (Thermo Fisher,
Waltham, MA, USA). Cryosections were stained with
Toluidine Blue to detect the presence of proteoglycans.
All stained cells were observed under an optical micro-
scope (Leica, Solms, Germany).
In vitro culture of human umbilical vein endothelial cells
In this study, HUVECs were isolated from human um-
bilical cords, which were obtained with informed con-
sent and local ethics approval [29]. Briefly, the cords
were washed twice with warmed phosphate-buffered sa-
line (PBS) to flush out blood and clots among other fac-
tors; HUVECs were digested with 0.5 mg/mL type II
collagenase (Sigma-Aldrich, St. Louis, MO, USA) for
30 minutes at 37°C and drawn out from the vessel wall
by medium 200 (M200) (Gibco) containing 10% FBS;
after centrifugation at 1,000 revolutions per minute for
5 minutes at room temperature, HUVECs were seeded
onto 1% gelatin-coated 25-cm2 cell culture flasks in
M200 + 10% FBS. Once HUVECs reached 90% conflu-
ence, they were further trypsinized and reseeded into
25-cm2 cell culture flasks and maintained in M200 sup-
plemented with 2% low serum growth supplement
(M200 + LSGS) (Cascade Biologics, Portland, OR, USA).
HUVECs at passage 2 were used in the experiments as
described below.
Isolation and purification of iMSCs-Exo
Exosomes were isolated from iMSC supernatant as pre-
viously described [30,31]. Briefly, 80% confluent iMSCs
were rinsed three times with PBS and cultured for
48 hours in a chemically defined medium (MesenGro
hMSC medium; stemRD, San Francisco, CA, USA). The
medium was obtained and centrifuged at 300 g for 10 mi-
nutes and at 2,000 g for 10 minutes at 4°C, and the cell
supernatant was filtered by using a 0.22-μm filter
sterilize Steritop™ (Millipore) to remove whole cells and
cellular debris. Afterwards, the supernatant was trans-
ferred to the upper compartment of an Amicon Ultra-15
Centrifugal Filter Units (Millipore) and centrifuged at
4,000 g at 4°C until the volume in the upper compart-
ment was reduced to approximately 200 μL. The ultrafil-
tration liquid was washed twice with PBS and re-
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quid was laid on top of 30% sucrose/D2O cushion in a
sterile Ultra-Clear™ tube (Beckman Coulter, Brea, CA,
USA) and centrifuged at 100,000 g for 60 minutes at 4°C
(Sorvall, Avanti J-26XP, fixed angle rotor; Beckman
Coulter). The fraction containing iMSCs-Exo was recov-
ered by using an 18-G needle and diluted in PBS and
was centrifuged at 4,000 g at 4°C in centrifugal filter
units until the final volume reached 200 μL. Exosomes
were stored at −80°C or used for downstream experi-
ments. In addition, an equal volume of serum-free
medium without culturing cells was obtained in the
same method of iMSCs-Exo and was centrifuged to
200 μL, which referred to the ‘control medium’. iMSCs-
Exo protein content was determined by using the
bicinchoninic acid assay (Thermo Fisher) as previously
described [32]. BSA ranged from 2 mg/mL to 25 μg/mL
to generate a calibration curve. The absorbance was read
at 562 nm by using a Microplate Reader (Bio-Rad La-
boratories, Berkeley, CA, USA).
Transmission electron microscopy
Transmission electron microscopy (TEM) was used to
identify the morphology of iMSCs-Exo. Briefly, iMSCs-
Exo were fixed in 3% glutaraldehyde for 2 hours and
washed with PBS two times. iMSCs-Exo were negatively
stained with 2% uranyl acetate for 30 seconds and ap-
plied to a continuous carbon grid. iMSCs-Exo were visu-
alized on a Hitachi H-7650 transmission electron
microscope (Hitachi, Tokyo, Japan), and images were
captured by using a digital camera (Olympus, Tokyo,
Japan).
Western blotting analysis
Western blotting was used to identify iMSCs-Exo
markers CD63, CD81, and CD9 [33]. Briefly, 5 × protein-
loading buffer was added directly to the iMSCs-Exo
sample and heated at 95°C for 5 minutes. Next, iMSCs-
Exo protein was loaded and resolved in 12% SDS-PAGE
polyacrylamide gels. The protein sample was run at
120 V for 45 minutes and transferred onto nitrocellulose
membranes (Whatman, Maidstone, Kent, UK) for
1.5 hours at 100 mA. The presence of CD63, CD81, and
CD9 was assessed by exposing the membranes to pri-
mary rabbit polyclonal anti-CD63 (1:1,000), anti-CD81
(1:1,000), and anti-CD9 (1:1,000) (Abcam, Cambridge,
UK). The membranes were washed three times in 1 ×
Tris-buffered saline with tween (TBST) for 5 minutes
and incubated for 1 hour in TBST containing horserad-
ish peroxidase-conjugated goat anti-rabbit secondary
antibody (Abcam). Proteins were detected by using en-
hanced chemiluminescence (Thermo Fisher) and imaged
by using an Image Quant LAS 4000 mini bio-molecular
imager (GE Healthcare, Uppsala, Sweden).Mouse hind-limb ischemia model and iMSCs-Exo injection
Animal study protocols were approved by the Institu-
tional Animal Care and Use Committee at Shanghai
Jiaotong University. Unilateral hind-limb ischemia was
produced by excising the common left iliac-femoral ar-
tery, from which the femoral artery merges from the
proximal origin to the distal point where it bifurcates
into the saphenous and popliteal arteries, and the
contralateral limb was used as internal control. One day
after femoral artery excision, mice (n = 20 for each
group) were randomly treated with multiple intramuscu-
lar injections (four injections in the quadriceps muscle)
in the ischemic leg, with the iMSCs-Exo group (200 μg
of iMSCs-Exo dissolved in PBS to final volume of
200 μL) or control group (the same volume of control
medium dissolved in PBS to 200 μL). To control the ef-
fect of the surgery, 20 mice received a sham operation at
the same position, in which the femoral artery was ex-
posed but not excised.
Blood flow measurements and the functional scores
Laser-Doppler Perfusion Imaging (Moor Instruments,
Devon, UK) was performed to monitor blood flow re-
covery in response to femoral artery excision at days 0,
7, 14, and 21 post-injection. The digital color-coded im-
ages were analyzed by comparing the blood flow ratio of
the ischemic (left) to the intact (right) leg expressed as
percentage perfusion. Severity of the ischemia was
scored by assessment of ambulatory impairment and tis-
sue damage as previously described [34]. Limb function
of all mice was scored at the same time as blood flow
measurements prior to sedation.
Histological and immunocytochemical analysis
We performed immunohistochemistry staining and im-
munocytochemical staining in accordance with the
protocol of the manufacturer. For immunocytochemical
staining, the mice were anesthetized and sacrificed by in-
traperitoneally injecting an overdose of chloral hydrate
at days 7, 14, and 21 post-injection. The quadriceps
muscle was carefully separated and fixed with 4% para-
formaldehyde overnight at 4°C and embedded in OCT.
Tissue sections were pre-incubated with sodium borohy-
dride (1 mg/mL in PBS) to reduce autofluorescence, in-
cubated overnight in 4°C with antibodies against CD31
(1:100; Abcam) and CD34 (1:100; Abcam), and incu-
bated for 1 hour with secondary antibody conjugated to
Alexa Fluor 594 (1:200; Abcam) and Alexa Fluor 488
(1:200; Abcam), respectively. Nuclei were stained with 4,
6-diamidino-2-phenylindole (DAPI) (0.5 μg/mL; Invitro-
gen, Grand Island, NY, USA). Isotype control antibodies
were used as negative controls. Tissues were mounted,
and the images were obtained by using a fluorescence
microscope (Leica). For immunohistochemistry staining,
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with paraformaldehyde and embedded in paraffin, and the
sections were stained with hematoxylin and eosin and ex-
amined under a light microscope (Leica) by two patholo-
gists who were blinded to the grouping conditions.
Endothelial cell migration assay
The real-time cell analyzer (RTCA) migration assay and
scratched wound assay were used to analyze the migra-
tion effect of iMSCs-Exo to HUVECs. The xCELLigence
system (Roche Applied Sciences, Basel, Switzerland)
used impedance as a readout and can continuously
monitor the cellular responses of biologically active
small-molecule compounds, producing time-dependent
cellular response profiles. The electronic readout of cell-
sensor impedance is displayed in real-time as CI, a value
directly influenced by cell attachment, spreading, or cell
proliferation or a combination of these. The CI value at
each time point is defined as Rn-Rb/Rb, where Rn is the
cell-electrode impedance of the well with the cells and
Rb is the background impedance of the well with only
medium [35]. HUVECs (4 × 104 cells per well) were
seeded into the upper chamber, and M200 containing
100 μg/mL iMSCs-Exo or control medium was added
into the lower chamber. The cells were incubated at 37°C
in 5% CO2 and monitored for 24 hours. For the scratched
wound assay, 2 × 105 cells were seeded into 12-well plates
and maintained at 37°C to permit cell adhesion and the
formation of a confluent monolayer. Next, these confluent
monolayers were ‘scratch’-wounded by using the tip of a
p200 pipet tip. The medium was removed and rinsed once
with PBS to remove the debris and smooth the edge of the
scratch and then replaced with fresh M200 + LSGS
medium containing 100 μg/mL iMSCs-Exo or control
medium. Wound closure was monitored by collecting
digital images at 0-, 12-, and 24-hour intervals after the
scratch, and digital images were captured by using an
inverted microscope (Leica). The images were obtained at
the same position before and after incubation. The experi-
ment was repeated three times. The level of wound clos-
ure was assessed by the ratio of closure area to initial
wound (0 hours) as follows:
Rn ¼ A0‐Anð Þ
A0
 100%;
where Rn represents the percentage of wound closure,
An represents the residual area of wound at the meter-
ing point (nh), and A0 represents the area of initial
wound (0 hours) [36].
Endothelial cell proliferation assay
A Cell Counting Kit-8 (CCK-8) assay (Dojindo, Kyushu
Island, Japan) was performed to assess cell proliferation.Briefly, HUVECs were seeded at 5 × 104 cells/mL
(100 μL/well) in a 96-well plate. After quiescence for
12 hours, cells were treated with M200 + LSGS contain-
ing different doses of iMSCs-Exo (0, 12.5, 25, 50, and
100 μg/mL) or control medium. At days 1, 2, 3, 4, and 5,
CCK-8 solution (10 μL) was added into medium and in-
cubated for 3 hours at 37°C. The amount of formazan
dye generated by cellular dehydrogenase activity was
measured for absorbance at 450 nm by using a micro-
plate reader. The optical density values of each well rep-
resented the survival/proliferation of HUVECs. All of
these experiments were performed in triplicate and re-
peated at least three times.
Endothelial cell capillary-like tube formation assay
In vitro capillary-like tube formation was evaluated on
growth factor-reduced Matrigel (BD Biosciences). At
least 30 minutes before the experiment, 96-well plates
were coated with Matrigel. Next, 2 × 104 HUVECs were
seeded onto the plated Matrigel in M200 with control
medium, M200 + LSGS, M200 with 50 μg/mL iMSCs-
Exo, and M200 with 100 μg/mL iMSCs-Exo. Tube for-
mation was quantified at 4, 6, and 18 hours. At each
time point, the capillary-like structures were imaged
from five random microscopic fields by using an
inverted microscope (Leica). Tube formations—(1) total
tube length per image and (2) total branch numbers per
image—were measured in a blind manner by an inde-
pendent observer.
Quantitative reverse-transcriptase polymerase chain
reaction
Quantitative reverse transcriptase-polymerase chain re-
action (qRT-PCR) for human-specific repeat sequences
was performed as previously described [37]. To identify
the expression level of Nanog, Oct4, and Msx1, total
RNA of iPSCs, induced iPSCs (at days 4, 6, 8, 10, 12,
and 14), and iMSCs was extracted by using Trizol re-
agent (Invitrogen). To test gene expression of HUVECs
after treatment with iMSCs-Exo, 8 × 105 HUVECs were
seeded onto six-well plates and cultured with M200 +
LSGS containing 50 μg/mL, 100 μg/mL iMSCs-Exo, or
control medium for 24 and 48 hours, and total RNA was
also extracted by using Trizol reagent (Invitrogen). The
following human primers were used: Nanog, Oct4,
Msx1, hypoxia-inducible factor-1α (HIF-1α), vascular
endothelial growth factor-A (VEGFA), VEGFB, placental
growth factor (PGF), basic fibroblast growth factor
(bFGF), transforming growth factor beta 1 (TGFB1),
Angiogenin (Angio), VEGF receptor 2 (kinase insert do-
main receptor, or KDR), bFGF receptor (bFGFR), and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(all from Sangon Biotech, Shanghai, China). The primer
sequences used in this study are summarized in Table 1.
Table 1 Primers used for quantitative reverse-transcriptase polymerase chain reaction
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The cDNA was diluted 1:10 in sterilized Milli-Q water.
Two microliters of diluted cDNA, 5 μL of SYBR-Green,
2.2 μL of Milli-Q water, and 0.8 μL of primer were added
into a 384-well plate, and amplification was performed
with a 10-minute pretreatment at 95°C, 95°C for 15 sec-
onds, and 60°C for 1 minute (40 cycles). Each qRT-PCR
was performed in triplicate for yield validation.
Enzyme-linked immunosorbent assay
To determine the level of angiogenic trophic factors se-
creted by HUVECs, 8 × 105 cells were seeded onto six-
well plates and cultured with M200 + LSGS containing
50 μg/mL, 100 μg/mL iMSCs-Exo, or control medium
for 24 and 48 hours. At the predetermined time points,
the cell supernatant was collected and centrifuged to re-
move cells and then stored at −80°C. VEGF, TGF-B1,
and Angiogenin secreted by HUVECs were quantified by
using specific VEGF, TGF-B1, and Angiogenin enzyme-
linked immunosorbent assay (ELISA) kits (all from
Westang Bio-tech, Shanghai, China) in accordance with
the instructions of the manufacturer.
Statistical analysis
All of the experiments were performed at least three
times. The data were shown as the mean ± standard
error of the mean. Unpaired Student’s t test was used for
statistical comparison of the data. P values of less than
0.05 were considered statistically significant.
Results
Differentiation of induced pluripotent stem cells into
mesenchymal stem cells
Using a modified one-step induction protocol [28], we
successfully induced iMSCs from three different iPSCs.Prior to induction, iPSCs tended to form packed clones
with a high nucleus/cytoplasm ratio (Figure 1A, i). How-
ever, the iPSCs began to lose their typical morphology
and formed a monolayer with a larger spindle-shaped
morphology at the border of the colonies after culture in
MSC medium for a few days (Figure 1A, ii). After being
passaged three times, the cells exhibited a uniform
fibroblastic-like morphology that resembled BMSCs
(Figure 1A, iii). qRT-PCR results showed that the tran-
script level of pluripotency-associated genes Nanog and
Oct4 were generally reduced during differentiation but
that the mesoderm gene Msx1 increased rapidly to a
high level (Figure 1B, i). The expression levels of Nanog
and Oct4 in iMSCs were approximately 103–5-fold below
that in iPSCs (Figure 1B, ii).
Surface antigen profiling of iMSCs using fluorescence-
activated cell sorting (FACS) analysis revealed a surface
antigen profile that was qualitatively similar to that
found in BMSCs, which was positive for CD29, CD44,
CD73, CD90, CD105, and CD146 but negative for
CD34, CD45, CD133, and HLA-DR (Figure 1C). Besides,
iPSCs cultured with mTESR1 before induction were
positive for CD90, weakly positive for CD29 and CD34,
and negative for CD44, CD45, CD73, CD105, CD133,
CD146, and HLA-DR (Additional file 1: Figure S1).
The differentiation potential of iMSCs was examined by
culturing in appropriate induction medium and determined
by corresponding staining. Osteogenic differentiation was
highly efficient: more than 90% of cells demonstrated posi-
tive staining with Alizarin Red (Figure 1D, i). After iMSCs
were induced with adipogenesis induction medium for
21 days, oil droplets were observed in more than 80% of
the cells (Figure 1D, ii). Chondrogenesis was also efficient:
more than 90% of cells produced proteoglycans in the
extracellular matrix as detected by using Toluidine Blue
Figure 1 Efficient differentiation of mesenchymal stem cells (MSCs) from human induced pluripotent stem cells (iPSCs) and characterization of
iMSCs-Exo. (A) Phase-contrast image of long-term cultured iPSC clone before differentiation (i), intermediate phase of induced iPSCs (ii), and
iMSCs (iii). (B) Quantitative reverse-transcriptase polymerase chain reaction analysis of the expression level of pluripotent genes (Nanog, Oct4, and
Msx1) in iPSCs during differentiation (i) and in iPSCs and iMSCs (ii). (C) Flow cytometric analysis of mesenchymal positive markers, such as CD29,
CD44, CD73, CD90, CD105, and CD146, and negative markers, such as CD34, CD45, CD133, and HLA-DR. Black histograms represent the isotype
controls, and the red solid peak represents the marker indicated. (D) Multi-differentiation potential of iMSCs. (i) Alizarin Red staining of osteogenic
mineralization (day 14). (ii) Oil Red O staining of small lipid droplets (day 21). (iii) Toluidine Blue staining of cartilaginous extracellular matrix (day 21).
(E) Morphology of iMSCs-Exo under transmission electron microscopy. (F) Western blotting analysis of exosomal CD63, CD81, and CD9 protein in iMSCs
and iMSCs-Exo. The culture medium served as the control. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iMSC, induced pluripotent stem
cell-derived mesenchymal stem cell; iMSCs-Exo, exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells.
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1% positive staining in the control group. These results
indicated that iMSCs were capable of multipotent
differentiation.
Characterization of iMSCs-Exo
We performed TEM to observe the morphology of
iMSCs-Exo, which were isolated by using ultrafiltration
combined with the purification method. TEM clearly re-
vealed that iMSCs-Exo exhibited a cup- or round-shaped
morphology with a size of 57 ± 11 nm (Figure 1E). Western
blotting (Figure 1F) confirmed the expression of exosomal
markers CD63, CD81, and CD9 in iMSCs-Exo.iMSCs-Exo promote blood perfusion and attenuate severe
hind-limb ischemia
To investigate the biological functions of iMSCs-Exo, we
used a mouse hind-limb ischemia model by performing
an excision of the left femoral artery and injected
iMSCs-Exo directly into the left quadriceps muscle. The
control group was injected with control medium. After
21 days, we observed robust differences in the ischemic
limb physiological status when compared with the iMSCs-
Exo group, control group, and sham group (Figure 2A,B).
Of the 20 mice in the control group, 14 (70%) had limb
loss and four (20%) demonstrated limb necrosis, with gan-
grenous tissue in the thigh and calf; and limb salvage was
Figure 2 (See legend on next page.)
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Figure 2 Transplantation of iMSCs-Exo improved blood flow and attenuated hind-limb ischemia. (A) Examples of the potential clinical outcomes
after femoral artery excision: no necrosis (i), necrosis of the phalanges (ii), necrosis above the ankle joint (iii), and complete necrosis of the limb
(iv). (B) At day 21 post-injection, the 3-group comparison showed a significant difference in the physiological status of the ischemic limb rated in
three levels: limb salvage, foot necrosis, and limb loss (n = 20 per group). (C) Laser Doppler flow imaging showed dynamic changes in blood
perfusion in limb ischemia of the 3-group at days 0, 7, 14, and 21 post-injection. (D) The ratio of blood flow in the left limb (ischemic) to right
limb (non-ischemic) was gradually recovered in iMSCs-Exo transplanted mice at day 21 (#P <0.05, day 0 versus 21); compared with the control
group, there was significantly improvement in the ratio of blood flow at day 21 (*P <0.05, iMSCs-Exo group versus control group). (E) At day 21
post-injection, hematoxylin-and-eosin staining for ischemic muscle showed that muscle had structural integrity in the sham group (i), whereas in
the control group, muscle had massive degeneration (ii); however, in the iMSCs-Exo group, muscle degeneration of the ischemic limb was largely
protected (iii). (F, G) In the iMSCs-Exo group, compared with the control group, the scores of ambulatory impairment and tissue damage were
significantly decreased at day 21 (*P <0.05, iMSCs-Exo group versus control group). iMSCs-Exo, exosomes derived from induced pluripotent stem
cell-derived mesenchymal stem cells.
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that received an iMSCs-Exo injection, two (10%) suffered
from limb loss and five (25%) demonstrated limb necrosis
in the calf and foot, and limb salvage was observed in 13
(65%). In the sham group, 20 mice recovered well with no
loss or necrosis (Figure 2B).
Tissue blood perfusion and flow rate were measured
by using laser Doppler at days 0, 7, 14, and 21 post-
injection (Figure 2C). Repeated-measure analysis of
variance (ANOVA) of blood perfusion in the 3-group
comparison revealed that iMSCs-Exo promoted blood
perfusion in the ischemic limb. At day 0, the iMSCs-Exo
group and control group similarly demonstrated low
levels of blood perfusion, and the sham group demon-
strated almost the same level compared with the normal
limb. At days 7 and 14, blood perfusion in the iMSCs-
Exo group was gradually recovered, whereas in the con-
trol group, it was at a poor recovery level. At day 21, the
difference in blood perfusion in the 3-group was prom-
inent; blood perfusion in the iMSCs-Exo group recov-
ered nearly the same as the normal limb, whereas blood
perfusion in the control group remained at a low level.
Blood perfusion in the iMSCs-Exo group was signifi-
cantly improved compared with that in the control
group (P <0.05; Figure 2D).
Hematoxylin-and-eosin staining for quadriceps muscle
revealed a significant difference in muscle integrity in
the 3-group analyses. Muscle in the sham group showed
structural integrity (Figure 2E, i). However, extensive
muscle degeneration was observed in the control group
when compared with the sham group (Figure 2E, ii). In
the iMSCs-Exo group, in contrast with the control
group, there was remarkably less muscle degeneration
(Figure 2E, iii).
Limb ambulatory impairment and tissue damage score
were used to evaluate ischemic limb function. Repeated-
measure ANOVA analysis demonstrated that scores of
ambulatory impairment and tissue damage were signifi-
cantly different between the iMSCs-Exo group and con-
trol group (Figure 2F,G). At day 3, there was a similar
dramatic limb function reduction in both the iMSCs-Exo group and control group, but limb function in the
sham group was less injured. At day 7, limb function in the
sham group recovered to a normal level, and limb function
reduction in the control group was more severe compared
with that in the iMSCs-Exo group (P <0.05). Next, we ob-
served that limb function gradually improved in the
iMSCs-Exo group after 7 days. In the iMSCs-Exo group,
compared with the control group, the ambulatory impair-
ment and tissue damage score were significantly reduced
at day 21 (P <0.05). These data indicated that iMSCs-Exo
can promote ischemic limb functional recovery.
iMSCs-Exo promote angiogenesis in the ischemic limb
Muscle recovery after ischemia is predominantly
dependent on angiogenesis because neovascularization
provides an exchange of nutrients and oxygen. Thus, in
this study, we used a morphometric analysis of immuno-
histochemical staining for the endothelial markers CD31
and CD34 to determine whether iMSCs-Exo can stimu-
late angiogenesis in ischemic muscle. As shown in
Figure 3A and B, representative images of CD31 staining
in the quadriceps muscle demonstrated that iMSCs-Exo
significantly increased the average microvessel density
(the number of microvessels per square millimeter of
area) compared with the control group (3.11-, 3.14-, and
3.46-fold increase relative to the control group on days
7, 14, and 21, respectively; P <0.05). Representative im-
ages of CD34 staining also show an increase in average
microvessel density compared with the control group
(2.56-, 2.64-, and 3.01-fold increase relative to the con-
trol group on days 7, 14, and 21, respectively; P <0.05).
In addition, after injection of iMSCs-Exo, the average
microvessel density was increased in a time-dependent
manner (P <0.05). These results suggested that trans-
plantation of iMSCs-Exo can stimulate angiogenesis in
the ischemic muscle.
iMSCs-Exo promote endothelial cell migration,
proliferation, and tube formation
We further investigated whether iMSCs-Exo can affect
HUVEC migration, proliferation, and tube formation.
Figure 3 Transplantation of iMSCs-Exo stimulated angiogenesis in the ischemic limb. (A) Mouse endothelial cells were stained red for surface
marker CD31 and green for surface marker CD34. Nuclei (blue) were stained with 4′, 6-diamidino-2-phenylindole (DAPI). Compared with the
control group, the iMSCs-Exo group had a significant microvessel density improvement at days 7, 14, and 21 (3.11-, 3.14-, and 3.46-fold increase
relative to the control group on days 7, 14, and 21 for CD31 staining, and 2.56-, 2.64-, and 3.01-fold increase relative to the control group on days
7, 14, and 21 for CD34 staining, respectively; *P <0.05). (B) Microvessel density in the control group rarely increased; however, in the iMSCs-Exo
group, there was a significant increase at days 7, 14, and 21 (*P <0.05). iMSCs-Exo, exosomes derived from induced pluripotent stem cell-derived
mesenchymal stem cells.
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cantly enhance the motility of HUVECs (P <0.05,
Figure 4A, i and ii). This result was confirmed by the
scratch wound assay (P <0.05, Figure 4B, i and ii). As
shown in Figure 4C, iMSCs-Exo stimulated endothelial
cell proliferation in a dose-dependent manner. HUVECs
cultured with iMSCs-Exo showed a more enhanced
proliferation ability compared with HUVECs cultured
with LSGS or control medium (P <0.05). Furthermore,
we employed a three-dimensional Matrigel assay to
examine the potential effects of iMSCs-Exo on tube for-
mation (Figure 4D, i to iii). Compared with the 4-group,
HUVECs cultured in LSGS and iMSCs-Exo formed
capillary-like structures, whereas HUVECs cultured inthe control medium rarely formed tube structures.
Moreover, there were no significant differences in tube
length and branch numbers in the LSGS group and
iMSCs-Exo group at 4 or 6 hours (P >0.05). However,
after 18 hours of culture, capillary-like structures in the
iMSCs-Exo group remained, whereas in the LSGS group,
the tube structures degraded. The tube length and
branch numbers in the 100 μg/mL iMSCs-Exo group were
significantly higher compared with the 50 μg/mL
iMSCs-Exo group or LSGS group (P <0.05). Because
endothelial cell migration, proliferation, and tube forma-
tion are key processes in angiogenesis, these results
demonstrated that iMSCs-Exo had the potential to pro-
mote angiogenesis.
Figure 4 iMSCs-Exo regulated human umbilical vein endothelial cell (HUVEC) migration, proliferation, and tube formation. Migration of HUVECs was
measured by using Real-Time Cell Analyzer (A, i, curve graph of RTCA; ii, Quantitative analysis of cell index at 4 h, 8 h, 12 h, 16 h, 20 h, 24 h for i.) and
scratched wound assay (B, i, optical micrographs of scratched wound assay; ii, quantitative analysis of migration index at 12 h and 24 h for i.). Compared
with the control group, iMSCs-Exo could improve the migration level of HUVECs (*P <0.05). Proliferation was measured by using the Cell Counting Kit-8
(CCK-8) (C). iMSCs-Exo can significantly stimulate HUVEC proliferation in a dose-dependent manner (*P <0.05). Tube formation test was performed on
growth factor-reduced Matrigel (D, i, optical micrographs of tube formation assay; ii, quantitative analysis of total tube length at 4 h, 6 h, 18 h for i; iii, quantitative
analysis of total branch points at 4 h, 6 h, 18 h for i.). There was no significant difference in branch number and total tube length of the capillary-like structures
for HUVECs cultured in low serum growth supplement (LSGS), 50 μg/mL, or 100 μg/mL iMSCs-Exo at 4 and 6 hours (P >0.05). However, after being cultured
for 18 hours, HUVECs cultured in 100 μg/mL iMSCs-Exo formed more capillary-like branches (*P <0.05), and the total tube length of the capillary-like
structures was much longer than that cultured in LSGS or 50 μg/mL iMSCs-Exo (*P <0.05). HUVECs cultured in control medium hardly formed capillary-like
structures. iMSCs-Exo, exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells; M200, Medium 200.
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molecules in human umbilical vein endothelial cells
Because exosomes can deliver proteins and genetic in-
formation to recipient cells to regulate gene transcrip-
tion and translation, we used qRT-PCR and ELISA to
detect the expression level of angiogenesis-related genes
(HIF-1α, VEGFA, VEGFB, PGF, bFGF, TGFB1, Angio-
genin, KDR, and bFGFR) and proteins (VEGF, TGFB1,and Angiogenin) after HUVECs were cultured with
iMSCs-Exo or control medium for 24 and 48 hours. As
shown in Figure 5A (i and ii), iMSCs-Exo could promote
angiogenesis-related gene expression (P <0.05). More-
over, iMSCs-Exo stimulated gene expression in a dose-
dependent manner. As shown in Figure 5B (i to iii),
HUVECs in the iMSCs-Exo group secreted more VEGF,
TGFB1, and Angiogenin compared with HUVECs in the
Figure 5 The expression level of angiogenesis-related molecules in human umbilical vein endothelial cells (HUVECs) increased after culturing with
iMSCs-Exo. Quantitative reverse-transcriptase polymerase chain reaction analysis of the expression level of angiogenesis-related genes (A) and
proteins (B) after culturing for 24 and 48 hours. (A) Compared with the control group, iMSCs-Exo upregulated angiogenesis-related gene
expression in a dose-dependent manner (*P <0.05) at 24 hours (i) and 48 hours (ii). (B) Compared with the control group, vascular endothelial
growth factor (VEGF) (i), transforming growth factor beta 1 (TGFB1) (ii), and Angiogenin (iii) secreted by HUVECs significantly increased after
culture with iMSCs-Exo (*P <0.05). angio, Angiogenin; BFGF, basic fibroblast growth factor; BFGFR, basic fibroblast growth factor receptor; HIF-1α,
hypoxia-inducible factor-1α; iMSCs-Exo, exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells; KDR, kinase insert
domain receptor; LSGS, low serum growth supplement; M200, Medium 200; PGF, placental growth factor.
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lated VEGF, TGFB1, and Angiogenin secretion also in a
dose-dependent manner. Taken together, these results
demonstrated that iMSCs-Exo can promote angiogenesis-
related gene expression and then protein secretion in a
dose-dependent manner.
Discussion
In the present study, we demonstrated for the first time that
transplantation of iMSCs-Exo could attenuate limb injury in
a mouse hind-limb ischemic model. We found that iMSCs-
Exo can robustly promote angiogenesis in ischemic muscle
and improve blood perfusion in the ischemic limb, which
were necessary for limb functional recovery. Furthermore,
we demonstrated that iMSCs-Exo can stimulate HUVEC
migration, proliferation, and tube formation. Moreover,
iMSCs-Exo can activate the expression of angiogenesis-
related molecules in HUVECs. Taken together, theseresults suggested that iMSCs-Exo can attenuate hind-limb
ischemic injury by promoting angiogenesis.
With the development of regenerative medicine, stem
cell transplantation is considered to have great potential
in treating ischemic diseases. Many studies have demon-
strated that transplanting isolated primary stem cells
have positive therapeutic effects in clinical studies and
experimental ischemic models [38,39]. In the stem cell
therapeutic field, adult MSCs have been largely studied
with regard to their high self-renewal capacity, differenti-
ation capacity, and low immunogenicity. Among all mul-
tipotent MSCs, those derived from bone marrow have
recently emerged as an attractive cell type for the treat-
ment of ischemic diseases [40,41]. However, large-scale
application of autologous BMSCs still presents chal-
lenges because patients can offer only a limited number
of BMSCs. In addition, BMSC proliferation and differen-
tiation potential significantly decline with the increasing
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few years, remarkable progress has been made in the
generation of clinically compliant and safer human
iPSCs by using virus- or vector-free methods or both
[42,43]. iPSCs become a promising cell source for clin-
ical application because they can be generated from the
patients’ somatic cells, which avoid the ethical issues and
immune rejection. Moreover, previous study has shown
that MSCs derived from iPSCs exhibited greater prolifer-
ative capacity than primary cultures of BMSCs [15]. In
the present study, we adopted a modified one-step
method to induce iPSCs into iMSCs, which displayed
typical mesenchymal characteristics. In contrast to iPSCs
and ESCs, iMSCs expressed no pluripotency genes, such
as Nanog and Oct4, which are thought to be essential
for maintaining the function of iPSCs and ESCs [44].
Currently, an increasing number of studies have re-
ported that improvement of tissue damage by stem cells
cannot be attributed to the differentiation of the deliv-
ered stem cells to replace injured cells. Their results in-
dicated that the beneficial effects of stem cell therapies
occur via secretory molecules in addition to cell replace-
ment, a process known as the paracrine effect [18].
Stem cells release growth factors, cytokines, chemokines,
and extracellular microvesicles into their surroundings,
which subsequently benefit cell regeneration or angio-
genesis [45]. Exosomes secreted by stem cells become an
important active component in the ‘paracrine hypothesis’
for their unique characteristics and positive effects in
the treatment of ischemic injury [19,46].
Many studies have shown that exosomes derived from
BMSCs can alleviate tissue damage and promote func-
tional recovery after ischemic injury [21,23]. Because
iMSCs have been demonstrated to have a strong thera-
peutic function, we proposed that iMSCs-Exo may also
have a powerful function in attenuating injury after
ischemia. We performed in vivo and in vitro experiments
to prove our hypothesis. Firstly, we used ultrafiltration
combined with a purification method to isolate iMSCs-
Exo. These iMSCs-Exo with a diameter of no more than
100 nm (57 ± 11 nm) expressed the exosome-specific
surface markers CD63, CD81, and CD9. Secondly, we
administered an intramuscular injection of iMSCs-Exo
into mice with ischemic limb to examine their thera-
peutic function. Consistent with our hypothesis, mice in
the iMSCs-Exo-treated group showed more limb salvage
and a slightly lesser degree of necrosis compared with
the control group. In addition, the ischemic limb treated
with iMSCs-Exo presented more abundant blood perfu-
sion, with higher microvessel density in ischemic muscle,
which indicated that iMSCs-Exo can promote angiogenesis
to attenuate limb injury. Thirdly, iMSCs-Exo promoted
HUVEC migration, proliferation, and tube formation as
demonstrated in vitro angiogenesis experiments, whichfurther confirmed the function of iMSCs-Exo in promoting
angiogenesis.
Exosomes are an integral part of the intercellular
microenvironment and act as regulators of cell-to-cell
communication. They can stimulate specific receptors in
recipient cells directly or deliver proteins and genetic in-
formation into recipient cells after being internalized.
These proteins or miRNAs can alter the bioactivity of
recipient cells via the activation of different signaling
pathways and regulation of protein translation [47].
Many reports have shown that exosomes derived from
MSCs contain various proteins and miRNAs. Proteomic
analysis showed that exosomes derived from MSCs har-
bor growth factors, cytokines, signaling molecules, and
adhesion molecules, such as VEGF, TGFB1, and
interleukin-8 (IL-8), which have been proven to contrib-
ute to the pro-angiogenic activity [48]. miRNA micro-
array results also showed that exosomes derived from
MSCs contain many miRNAs, including miR210,
miR126, miR132, and miR21, which have been proven to
play important roles in angiogenesis [49]. Umezu et al.
demonstrated that exosomes derived from multiple
myeloma cells can transfer miR135b to endothelial
cells to directly suppress factor-inhibiting hypoxia-
inducible factor 1 (FIH-1), and activate HIF-1α via
the HIF-FIH signaling pathway, leading to the over-
production of angiogenic cytokines such as VEGF,
angiopoietin-1, and osteopontin, therefore resulted in
endothelial cell migration, proliferation, and angio-
genesis [50]. Tadokoro et al. reported that exosomes
derived from hypoxic K562 cells transfer miR210 into
endothelial cells to downregulate Ephrin-A3 (EFNA3)
gene expression and thereby enhance tube formation
of endothelial cells [51]. A recent study by Sheldon
et al. has shown that endothelial exosomes transfer
Delta-like ligand 4 (Dll4) protein to neighboring endo-
thelial cells, leading to an inhibition of Notch signaling
and an increased capillary-like structure formation
in vitro and in vivo [52]. Therefore, these results
indicate that angiogenesis-related proteins and miRNAs
may be the main components in exosomes to exert their
pro-angiogenesis function.
In our experiment, we found that iMSCs-Exo can
stimulate angiogenesis-related gene expression and pro-
tein secretion. After being cultured with iMSCs-Exo,
HUVECs expressed higher levels of PGF, HIF-1α,
TGFB1, VEGFA, VEGFB, Angiogenin, bFGF, KDR, and
bFGFR and secreted more VEGF, TGFB1, and Angio-
genin. These data indicated that iMSCs-Exo can activate
an array of angiogenesis-related gene expression and
protein secretion after their uptake by HUVECs. It has
been well demonstrated that simultaneous delivery of
multiple angiogenic factors is more effective than the de-
livery of a single angiogenic factor in enhancing vessel
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Exo may play a more powerful pro-angiogenesis function
than that of a single recombinant angiogenic factor
supplement.
Conclusions
The present study demonstrated that iMSCs-Exo trans-
plantation can protect against ischemic injury in an experi-
mental mouse hind-limb ischemic model. One potential
mechanism for exerting the protective function of iMSCs-
Exo was the stimulation of angiogenesis in ischemic
muscle. Overall, the application of iMSCs-Exo may be a
novel therapeutic approach in the treatment of ischemic
disease.
Additional file
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HLA-DR. Black histograms represent the isotype controls, and the red
solid peak represents the indicated marker.
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